Global Peripartum Cardiomyopathy Market, By Diagnosis (Electrocardiography, Cardiac MRI), End-User (Hospitals, Research Institutes, Specialty Clinics) , Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029
Peripartum Cardiomyopathy Market Analysis and Size
The peripartum cardiomyopathy market is expected to witness significant growth during the forecast period. The increase in the facilities for patients affected by this severe disease syndrome has been directly impacting the growth of global peripartum cardiomyopathy market. The prevalence of this disease is 4.84 per 10,000 live births. The increasing need for an accurate and appropriate diagnosis for these conditions is expected to significantly impact the market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the peripartum cardiomyopathy market in the forecast period 2022-2029. The global peripartum cardiomyopathy market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Peripartum cardiomyopathy is a potentially life-threatening condition typically characterized as heart failure with reduced ejection fraction (HFrEF) in women's last month of pregnancy or sometimes in the months after delivery. It is more often associated ith twin pregnancy and smoking, T-wave inversion and cardiomegaly This diseased condition is increasing and thus it is very important to the healthcare sector.
Peripartum Cardiomyopathy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Diagnosis (Electrocardiography, Cardiac MRI),End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Vertex Pharmaceuticals Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.); Amgen Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.), Pfizer Inc (U.S.), PerkinElmer Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.); BioMarin (U.S.), Sarepta Therapeutics (U.S.)
|
|
Market Opportunities
|
|
Global Peripartum Cardiomyopathy Market Dynamics
Drivers
- Increase in Diagnostic Tests
Different diagnostic tests used to treat peripartum cardiomyopathy market are boosting the market growth. Multiple tests such as electrocardiography, cardiac MRI to detect the presence of specific defects. Thus, it acts as a major driver in the market growth.
- Increasing Awareness of Healthcare Infrastructure
Another significant factor influencing the growth rate of peripartum cardiomyopathy market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
Opportunities
- Increase in Smoking and Lifestyle Changes
Cigarette smoking is one of the leading cause of preventable disease and death in the U.S. It accounts for more than 480,000 deaths every year. In addition to this, the lifestyle changes that are attained by today’s population such as unhealthy lifestyle, poor diet, stress and many such factors altogether contribute to the developing opportunities of the market.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global peripartum cardiomyopathy market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global peripartum cardiomyopathy market over a forecast period.
- High Cost
The huge expenditure required for the treatment processes surely hamper the market growth. Several market players make huge investment in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This peripartum cardiomyopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the peripartum cardiomyopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Peripartum Cardiomyopathy Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period.
The load on healthcare facilities and professionals was growing in tandem with the rapid increase in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the peripartum cardiomyopathy market. The epidemic has put a strain on the treatment procedures overall. As a result of the lockdown and travel restrictions, the number of hospitals has decreased and countless drives have been cancelled around the world.
G Global Peripartum Cardiomyopathy Market Scope
The peripartum cardiomyopathy market is segmented on the basis of diagnosis, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Electrocardiography
- Cardiac MRI
End-User
- Hospitals
- Research Institutes
- Specialty Clinics
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Peripartum Cardiomyopathy Market Regional Analysis/Insights
The peripartum cardiomyopathy market is analysed and market size insights and trends are provided by diagnosis, distribution channel and end-user as referenced above.
The major countries covered in the peripartum cardiomyopathy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period due to the prevalence of the disease.
Asia-Pacific is considered to have the most lucrative period due to increasing number of patient population and surging level of disposable income in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Peripartum Cardiomyopathy Market Share Analysis
The peripartum cardiomyopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to peripartum cardiomyopathy market
Key players operating in the peripartum cardiomyopathy market include:
- Alexion Pharmaceuticals, Inc. (U.S.)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- Vertex Pharmaceuticals Incorporated (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Amgen Inc. (U.S.)
- Jazz Pharmaceuticals, Inc. (U.K.)
- Pfizer Inc (U.S.)
- PerkinElmer Inc (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BioMarin (U.S.)
- Sarepta Therapeutics (U.S.)
SKU-